Patents by Inventor James P. Fandl

James P. Fandl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250206829
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Application
    Filed: November 1, 2024
    Publication date: June 26, 2025
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Patent number: 12054751
    Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
    Type: Grant
    Filed: December 15, 2022
    Date of Patent: August 6, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Darya Burakov, James P. Fandl
  • Publication number: 20240036043
    Abstract: The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. Nucleic acids encoding the high affinity antibodies can then be cloned into other lymphoid and non-lymphoid cells where the antibody can be expressed and from which the antibodies can be secreted.
    Type: Application
    Filed: October 2, 2023
    Publication date: February 1, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang CHEN, Robert BABB, James P. FANDL
  • Publication number: 20240018553
    Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Application
    Filed: September 6, 2023
    Publication date: January 18, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
  • Patent number: 11808766
    Abstract: The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. Nucleic acids encoding the high affinity antibodies can then be cloned into other lymphoid and non-lymphoid cells where the antibody can be expressed and from which the antibodies can be secreted.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: November 7, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Robert Babb, James P. Fandl
  • Patent number: 11788102
    Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: October 17, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
  • Publication number: 20230322956
    Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antibodies including bispecific antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing an expression-enhancing locus.
    Type: Application
    Filed: November 10, 2022
    Publication date: October 12, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert BABB, Darya BURAKOV, Gang CHEN, James P. FANDL
  • Publication number: 20230295583
    Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
    Type: Application
    Filed: December 15, 2022
    Publication date: September 21, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Darya Burakov, James P. Fandl
  • Publication number: 20230130799
    Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antigen-binding proteins including monospecific and bispecific antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing multiple expression-enhancing locus.
    Type: Application
    Filed: September 28, 2022
    Publication date: April 27, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert BABB, Darya BURAKOV, Gang CHEN, James P. FANDL, Yu ZHAO
  • Publication number: 20230094591
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Application
    Filed: May 20, 2022
    Publication date: March 30, 2023
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Patent number: 11560550
    Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: January 24, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Darya Burakov, James P. Fandl
  • Patent number: 11530277
    Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antibodies including bispecifc antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing an expression-enhancing locus.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: December 20, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert Babb, Darya Burakov, Gang Chen, James P. Fandl
  • Patent number: 11512144
    Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antigen-binding proteins including monospecific and bispecifc antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing multiple expression-enhancing locus.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: November 29, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Robert Babb, Darya Burakov, Gang Chen, James P. Fandl, Yu Zhao
  • Patent number: 11370843
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: June 28, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Patent number: 11268109
    Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: March 8, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
  • Publication number: 20210254022
    Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
    Type: Application
    Filed: May 4, 2021
    Publication date: August 19, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Darya Burakov, James P. Fandl
  • Publication number: 20210171984
    Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Application
    Filed: February 12, 2021
    Publication date: June 10, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
  • Publication number: 20210009698
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Application
    Filed: January 28, 2020
    Publication date: January 14, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Publication number: 20200326349
    Abstract: A method of detecting and isolating cells that produce a secreted protein of interest (POI), for example, an antibody, comprising: a) providing a eukaryotic cell comprising (i) a nucleic acid encoding the POI, and (ii) a nucleic acid encoding a cell surface capture molecule, which comprises a membrane anchor and is capable of binding the POI; (b) culturing the cell under conditions in which the POI and cell surface capture molecule are expressed, and a POI-cell surface capture molecule complex is formed intracellularly and displayed on the cell surface; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.
    Type: Application
    Filed: February 12, 2020
    Publication date: October 15, 2020
    Inventors: James P. Fandl, Gang Chen, Neil Stahl, George D. Yancopoulos
  • Patent number: 10752698
    Abstract: The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. Nucleic acids encoding the high affinity antibodies can then be cloned into other lymphoid and non-lymphoid cells where the antibody can be expressed and from which the antibodies can be secreted.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: August 25, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Robert Babb, James P. Fandl